Bluebird Bio (BLUE, Financial) experienced a significant drop in its stock price, declining by 5.67%. The shares are currently trading at $0.491, with a trading volume of 3.72 million shares, a turnover rate of 1.92%, and showing a price amplitude of 4.76%.
The recent financial report indicates that Bluebird Bio generated $16.10 million in revenue, with a net loss of $81.39 million. The earnings per share (EPS) stand at -$0.42, and the gross profit is reported at -$12.85 million. The price-to-earnings (P/E) ratio is -0.22.
In terms of analyst ratings, among 10 institutions, 30% recommended buying, 60% suggested holding, and 10% advised selling the stock.
In the broader biotechnology sector, where Bluebird Bio is positioned, there was a minor overall increase of 0.10%. Noteworthy stocks in the sector showing significant gains include Nkgen Biotech Inc C/Wts and Portage Biotech Inc. Additionally, Aditxt, Inc., Bio-Path Holdings, Inc., and Gri Bio, Inc. demonstrated high activity levels and turnover rates. Stocks with large price fluctuations included Nkgen Biotech Inc C/Wts and Virios Therapeutics, Inc.
Bluebird Bio Inc is a biotechnology firm specializing in developing gene therapies for severe genetic diseases using its proprietary lentiviral vector (LVV) gene addition platform. The company operates as a single division, focusing on potential transformative gene therapies.
